Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial - Cohen,M.; Bhatt,D.L.; Alexander,J.H. (Circulation, 2007)